Skip to content
    JYNT
    Earnings call· Jun 2026(Q2 FY26)

    JOINT Q2 FY26 earnings call JYNT

    Aug 6, 2026 Source

    Executive summary

    The Joint Corp. Q2 FY26 — Re-franchising Nears Completion, Driving Profitability and Patient Retention

    The Joint Corp. continued its "Joint 2.0" initiative in Q2 FY26, nearing completion of its re-franchising efforts to transition to a capital-light franchisor model. This strategic shift is driving improved profitability and free cash flow, with significant year-over-year increases in net income and adjusted EBITDA. The company also achieved its best patient retention rate in over five years, attributed to new flexible plan options and targeted marketing, despite a decline in system-wide sales and negative comparable sales.

    Highlights

    5

    • Consolidated net income improved by $560,000 year-over-year to $653,000.

    • Adjusted EBITDA from continuing operations increased by $1.4 million year-over-year to $1.5 million.

    • Cash flow from operating activities grew 152% year-over-year to $2.2 million.

    • Free cash flow increased by $1.6 million year-over-year to $1.9 million.

    • Patient retention rate was the best in over five years, driven by new flexible plan options.

    Concerns

    4

    • System-wide sales declined 3.7% year-over-year to $128 million.

    • Comp sales were negative 2.8% in Q2 FY26.

    • New clinic openings guidance for FY26 lowered to 22-26 from 30-35.

    • Net clinic count at year-end 2026 is expected to be lower than 2025 due to portfolio optimization and closures.

    Guidance & targets

    12
    CategoryTargetConfidence
    FY26 System-wide sales
    $519 million to $552 million
    high materiality
    High
    FY26 Comp sales
    negative 3% to positive 3%
    high materiality
    High
    FY26 Consolidated adjusted EBITDA
    $12.5 million to $13.5 million
    high materiality
    High
    FY26 New franchise clinic openings
    22 to 26
    medium materiality
    High
    Comp sales trend
    improve throughout the balance of this year
    high materiality
    High
    Gross margin (pure play franchisor model)
    between 83% and 85% of revenues
    high materiality
    High
    G&A expense (pure play franchisor model)
    between 40% and 42% of revenues
    high materiality
    High
    CapEx (pure play franchisor model)
    approximately 3% of revenues
    medium materiality
    High
    Free cash flow conversion (pure play franchisor model)
    between 60% and 70%
    high materiality
    High
    Adjusted EBITDA margin (pure play franchisor model)
    19% to 21%
    high materiality
    High
    Net income margin (pure play franchisor model)
    13% to 15%
    high materiality
    High
    Long-term franchise clinics in U.S.
    more than 1,800
    high materiality
    High

    Operational metrics

    35
    Consolidated net income improvement
    $560,000year-over-year
    Q2 FY26

    reflecting the improved operating leverage of the current business.

    Adjusted EBITDA from continuing operations increase
    $1.4 millionyear-over-year
    Q2 FY26

    reflecting the improved operating leverage of the current business.

    Patient retention rate
    best in over five years
    Q2 FY26

    a direct result of the new flexible and expanded plan options introduced earlier this year.

    Share repurchases
    $677,000
    Q2 FY26
    Regional developer territory buybacks
    3bringing the year-to-date total to four
    Q2 FY26
    Revenue growth
    14%year-over-year
    Q2 FY26

    to $15.2 million, reflecting the shift to our pure play franchisor revenue model.

    Revenue
    $15.2 millionup 14% year-over-year
    Q2 FY26
    Adjusted EBITDA from continuing operations
    $1.5 millioncompared to $88,000 in Q2 2025
    Q2 FY26

    an increase of $1.4 million, underscoring the operating leverage we are generating in our new franchisor model.

    Consolidated net income
    $653,000compared to $93,000 in the prior year period
    Q2 FY26
    Clinics with ownership transferred
    32
    to date

    remaining 13 clinics are being operated by the buyer under management service agreements.

    Clinics with signed asset purchase agreement
    4
    to date
    Clinics with ownership transferred
    6
    to date

    remaining 15 clinics also operating under management service agreements.

    Remaining company-owned or managed clinics
    3
    post-re-franchising
    2025 class clinic openings performance
    outperform prior year cohorts
    2025

    new clinics so far this year are performing even better.

    AI visibility score
    high 70sheld steady
    Q2 FY26

    keeping us ahead of competitors on key search topics.

    Clinics opted for pricing increases
    over 500
    July

    rolled out $5 and $10 pricing increases.

    Cost of revenues decrease
    11%compared to the same period last year
    Q2 FY26

    primarily reflecting lower regional developer royalty costs as we continue to reacquire RD territories.

    Selling and marketing expenses increase
    40%compared to the same period last year
    Q2 FY26

    funded incremental investments in patient acquisition and brand initiatives.

    Selling and marketing expenses
    $4.9 millionup 40% year-over-year
    Q2 FY26
    G&A expenses decrease
    2%compared to the same period last year
    Q2 FY26

    to $7.6 million compared to $7.7 million in the same period last year.

    G&A expenses
    $7.6 milliondown 2% year-over-year
    Q2 FY26
    Non-recurring G&A expenses
    $500,000
    Q2 FY26

    relates to expenses incurred for RD buyback and expenses that will not be recurring post-re-franchising.

    Net loss from continuing operations
    $251,000compared to a loss of $990,000 in the same period last year
    Q2 FY26
    Unrestricted cash balance
    $22.2 millioncompared to $23.6 million at the end of 2025
    Q2 FY26 end
    Line of credit capacity
    $20 million
    Q2 FY26

    fully undrawn.

    Remaining share repurchase authorization
    $3.8 million
    Q2 FY26 end

    under the $12 million authorization approved in November 2025.

    Annualized reduction in RD royalties
    $630,000
    annualized

    from the four RD territories completed year-to-date, partially offset by internal costs.

    Total clinic count
    941
    Q2 FY26 end
    Clinics opened
    5
    Q2 FY26
    Clinics closed
    7
    Q2 FY26
    Clinics re-franchised
    29
    Q2 FY26
    New clinics break-even point
    under six monthseven earlier
    2026

    outperform similar to 2025 and are reaching their break-even point even earlier.

    Remaining proceeds from re-franchising
    a little bit less of $500,000
    future

    once all ownership transfers are done.

    Align One plan cost
    $35
    per month

    given these patients another option to choose from other than and the standard wellness plan.

    Pricing initiatives impact
    low single-digit range
    Q2 FY26

    expected to be at the high end of that low single-digit range in the second half.

    Industry KPIs

    5
    MetricValueDetails
    Utilization trendsunder six months
    Same facility volumesnegative 2.8%%
    Client retention new winsbest in over five years
    Membership covered lives by linesequential improvement
    Adjusted EPS EBITDA leverage guidance$1.5 millionUSD

    Deals & partnerships

    4
    Unnamed buyerSale of clinics, transitioning to management service agreements pending lease assignments.

    Ownership has been transferred for 32 clinics to date and the remaining 13 clinics are being operated by the buyer under management service agreements while lease assignments are finalized for the Southern California bundle.

    Unnamed buyerSale of clinics.

    A signed asset purchase agreement is in place for four clinics for the Northern California bundle.

    Unnamed buyerSale of clinics, transitioning to management service agreements pending lease assignments.

    Ownership has been transferred for six clinics to date, with the remaining 15 clinics also operating under management service agreements pending lease reassignments for the Southeast bundle.

    Regional DevelopersAcquisition of regional developer territories to optimize portfolio economics.

    Completed three regional developer territory buybacks in the quarter, bringing the year-to-date total to four.

    Risks & headwinds

    4
    System-wide sales declineQ2 FY26

    3.7% year-over-year decline to $128 million

    Mitigation: Focus on driving growth through franchise system support, new patient acquisition, and long-term network development.

    Negative comparable salesQ2 FY26

    Negative 2.8% in Q2 FY26

    Mitigation: Flexible membership options, pricing optimization, improving active member trends, lead generation, and winning back lapsed patients. Expected to improve throughout H2 FY26.

    Lower net clinic countFY26

    Net clinic count at the end of 2026 will be lower than 2025

    Mitigation: Strategic portfolio optimization to reshape around stronger operators and healthier sites, building a more durable foundation for future growth.

    Lower new clinic openings guidanceFY26

    FY26 guidance lowered to 22-26 from 30-35

    Mitigation: Focus on quality over quantity, bringing on well-capitalized franchisees with multi-site operating experience.

    What to watch in Q3 FY26

    5

    Comp sales trend

    Q3 FY26, Q4 FY26
    CurrentNegative 2.8% in Q2 FY26, 'a bit better' in July
    TargetImprovement throughout H2 FY26, with Q4 higher than Q3

    Why it matters

    Indicates the effectiveness of patient retention, pricing, and marketing strategies, crucial for revenue growth.

    We expect comp sales to improve in the second half of the year, with the fourth quarter expected to be higher than the third quarter.

    Q&A highlights

    5

    How is the company operating in the new AI search environment to ensure customer click-through to its website, given changes like Google's click rates going to zero?

    Management stated they stay ahead through three ways: feedback from 260 local franchisees, a dedicated digital marketing team monitoring algorithm changes across platforms, and objective measurement systems. Their AI search score has improved from the low 70s to the high 70s.

    “For when we started this journey sometime I would say late last year, our AI score, search score was in the low 70s, 71 to be precise. And for the last several months now, we have been in the high 70s.”

    asked by Nicholas Sherwood · answered by Unknown Speaker

    2 min read6 chapters

    Detailed Narrative

    01

    Re-franchising Progress and Capital-Light Model

    The company is nearing completion of its re-franchising initiative, with ownership transferred for 32 clinics in Southern California and 6 clinics in the Southeast bundle. Remaining clinics are operating under management service agreements pending lease assignments. This transition positions the company as a capital-light, pure-play franchisor, expected to realize full benefits in H2 2026, leading to higher profitability and stronger free cash flow. Only three company-owned or managed clinics will remain once transfers are finalized.

    02

    Patient Retention and Flexible Plan Options

    Patient retention rates reached a five-year high in Q2 FY26, directly attributed to the introduction of new flexible and expanded plan options earlier this year. These options, such as the Align One plan ($35 for one visit/month, additional visits for $25), have significantly improved conversion rates for lapsed patients and are reducing attrition. The company is actively targeting lapsed patients with marketing efforts, including an August promotion.

    03

    Digital Marketing and AI Optimization

    The Joint Corp. is actively optimizing its digital marketing strategy, including SEO and AI visibility. The company's AI visibility score has consistently held in the high 70s, outperforming competitors. This focus drives higher organic traffic and lead quality to local clinic microsites, supported by continuous monitoring of algorithm changes and local franchisee feedback. This strategy aims to effectively capture demand and improve patient acquisition.

    04

    Pricing Strategy and Impact

    The company expanded its $5 and $10 pricing increases to over 500 clinics in July. Feedback indicates no meaningful patient pushback, and the strategy is designed to optimize revenue without negatively impacting patient acquisition or retention. Pricing changes are primarily applied to new patients, with the full impact expected to materialize over time⏳ as more patients transition to the current pricing model, contributing to low single-digit revenue growth.

    05

    Clinic Portfolio Optimization

    The company opened 5 clinics, closed 7, and re-franchised 29 clinics in Q2 FY26, reflecting a strategy to optimize the portfolio for quality and performance. New clinics opened in 2026 are outperforming prior cohorts and reaching break-even in under six months. The overall net clinic count is expected to be lower by year-end 2026, but this is seen as building a stronger, more durable foundation for future growth, with potential for over 1,800 franchise clinics in the U.S. alone.

    06

    Capital Allocation and RD Buybacks

    The company repurchased approximately 82,000 shares for $677,000 at an average price of $8.23 per share, with $3.8 million remaining under the $12 million authorization. Additionally, three regional developer (RD) territory buybacks were completed in Q2 (four year-to-date), which are expected to reduce RD royalties by approximately $630,000 on an annualized basis, partially offset by internal management costs. These actions reflect conviction in long-term value and commitment to stockholder returns.

    AI-generated summary of the company’s earnings call. Not investment advice.